| 摘要 |
The present disclosure includes various embodiments directed to a solubilised capsule formulation of asunaprevir, 1,1-dimethylethyl [(1S)-1-{ [(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrr olidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate, and to methods of treating hepatitis C virus (HVC) infection. The formulations are solubilised by medium-chain fatty acid triglycerides, combinations of mono, di and triglycerides of long-chain fatty acids; mono- and di- long-chain fatty acid esters of polyethylene glycol (commonly known as polyoxyethylated glycerides, i.e., oleoyl polyoxylglycerides and linoleoyl polyoxylglycerides); glycerol monocaprylocaprate, glycerol monocaprylate, glycerol mono/dicaprate, and the propylene glycol mono- and diesters of medium-chain fatty acids such as propylene glycol monocaprylate, propylene glycol monolaurate, propylene glycol dilaurateand, and combinations thereof. |
